DK4118200T3 - Muteret beta-glucocerebrosidase med forbedret stabilitet - Google Patents

Muteret beta-glucocerebrosidase med forbedret stabilitet

Info

Publication number
DK4118200T3
DK4118200T3 DK21752123.6T DK21752123T DK4118200T3 DK 4118200 T3 DK4118200 T3 DK 4118200T3 DK 21752123 T DK21752123 T DK 21752123T DK 4118200 T3 DK4118200 T3 DK 4118200T3
Authority
DK
Denmark
Prior art keywords
glucocerebrosidase
improved stability
mutated beta
mutated
beta
Prior art date
Application number
DK21752123.6T
Other languages
Danish (da)
English (en)
Inventor
Fabrizio Comper
Amit Nathwani
Jenny Mcintosh
Romuald Corbau
Azadeh Kia
Carlos Miranda
Original Assignee
Spur Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2011813.9A external-priority patent/GB202011813D0/en
Priority claimed from GBGB2100648.1A external-priority patent/GB202100648D0/en
Priority claimed from GBGB2105924.1A external-priority patent/GB202105924D0/en
Application filed by Spur Therapeutics Ltd filed Critical Spur Therapeutics Ltd
Application granted granted Critical
Publication of DK4118200T3 publication Critical patent/DK4118200T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK21752123.6T 2020-07-29 2021-07-29 Muteret beta-glucocerebrosidase med forbedret stabilitet DK4118200T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2011813.9A GB202011813D0 (en) 2020-07-29 2020-07-29 Polypeptide
GBGB2100648.1A GB202100648D0 (en) 2021-01-18 2021-01-18 Polypeptide
GBGB2105924.1A GB202105924D0 (en) 2021-04-26 2021-04-26 Polypeptide
PCT/GB2021/051969 WO2022023761A2 (en) 2020-07-29 2021-07-29 Polypeptide

Publications (1)

Publication Number Publication Date
DK4118200T3 true DK4118200T3 (da) 2025-12-08

Family

ID=77265101

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21752123.6T DK4118200T3 (da) 2020-07-29 2021-07-29 Muteret beta-glucocerebrosidase med forbedret stabilitet

Country Status (16)

Country Link
US (1) US20240261433A1 (https=)
EP (2) EP4118200B1 (https=)
JP (1) JP2023535808A (https=)
KR (1) KR20230042513A (https=)
CN (1) CN116322744A (https=)
AU (1) AU2021316875B2 (https=)
BR (1) BR112023001583A2 (https=)
CA (1) CA3189801A1 (https=)
DK (1) DK4118200T3 (https=)
ES (1) ES3057448T3 (https=)
FI (1) FI4118200T3 (https=)
HR (1) HRP20251591T1 (https=)
IL (1) IL299811A (https=)
MX (1) MX2023001137A (https=)
PT (1) PT4118200T (https=)
WO (1) WO2022023761A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025122912A1 (en) 2023-12-08 2025-06-12 Denali Therapeutics Inc. Modified glucocerebrosidase polypeptides and methods of use thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
CN118086341B (zh) * 2024-04-25 2024-08-02 上海凌医生物科技有限公司 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框
WO2026006173A1 (en) 2024-06-24 2026-01-02 Denali Therapeutics Inc. Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1775901A (en) * 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
AU2352201A (en) * 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
EP2154969B1 (en) 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
SI2638152T1 (sl) * 2010-11-08 2016-12-30 Amicus Therapeutics, Inc. Variantni in rekombinantni proteini beta-glukocerebrozidaze s povišano stabilnostjo in povišano ohranjeno katalitično aktivnostjo
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9574184B2 (en) * 2013-09-25 2017-02-21 Children's Hospital Medical Center Lysosomal protein targeting sequence and therapeutic applications of same
KR102450833B1 (ko) * 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
EP3692075A4 (en) 2017-10-03 2022-02-09 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
WO2020012149A1 (en) 2018-07-13 2020-01-16 Ucl Business Ltd Glucocerebrosidase gene therapy
WO2020012164A1 (en) 2018-07-13 2020-01-16 Ucl Business Ltd Glucocerebrosidase gene therapy
US20220125892A1 (en) * 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides

Also Published As

Publication number Publication date
KR20230042513A (ko) 2023-03-28
WO2022023761A2 (en) 2022-02-03
EP4643868A3 (en) 2026-04-08
JP2023535808A (ja) 2023-08-21
ES3057448T3 (en) 2026-03-02
FI4118200T3 (fi) 2025-12-12
CN116322744A (zh) 2023-06-23
EP4118200B1 (en) 2025-10-08
IL299811A (en) 2023-03-01
EP4643868A2 (en) 2025-11-05
BR112023001583A2 (pt) 2023-02-14
PT4118200T (pt) 2026-01-08
CA3189801A1 (en) 2022-02-03
MX2023001137A (es) 2023-02-22
WO2022023761A3 (en) 2022-03-10
EP4118200A2 (en) 2023-01-18
US20240261433A1 (en) 2024-08-08
AU2021316875A1 (en) 2023-02-23
AU2021316875B2 (en) 2026-04-02
HRP20251591T1 (hr) 2026-01-30

Similar Documents

Publication Publication Date Title
DK4118200T3 (da) Muteret beta-glucocerebrosidase med forbedret stabilitet
DK3788314T3 (da) Oxyfuel-klinkerfremstilling med speciel oxygentilføjelse
JP1709677S (ja)
EP3397756A4 (en) IMMUNEFFECTOR CELL THERAPIES WITH IMPROVED EFFICACY
EP3580354A4 (en) HIGH THROUGHPUT SINGLE CELL POLYOMICS
DK3426917T3 (da) Flydende vindmølle med dobbelt turbine med vertikal akse med forbedret ydelse
BR112017028486A2 (pt) instrumento para higiene bucal e cerdas de monofilamento para uso com o mesmo
DK3788912T3 (da) Stolearrangement
DK3827895T3 (da) Rørreaktor med fast leje
EP3947142A4 (en) ASYMMETRICAL MULTIROTOR
LT3752516T (lt) Cikliniai dinukleotidai kaip priešvėžiniai agentai
DK3986920T3 (da) Tnfr2-agonister med forbedret stabilitet
IL307651A (en) An anti-tslp fab with improved stability
JP1717607S (ja)
JP1711205S (ja) いす
EP3387680A4 (en) AVALANCHE PHOTO DETECTORS
DK3225145T3 (da) Sugehoved med forbedret sugekanal
IL278161A (en) Solid dosage form having excellent stability
EP3938378C0 (en) NOROVIRUS-LIKE PARTICLES WITH ENHANCED STABILITY
PL3880802T3 (pl) Udoskonalony sposób wytwarzania komórek T
EP3724324C0 (en) CARBOXYESTERASE BIOCATALYSTS
EP3554471A4 (en) ORAL CARE COMPOSITIONS INCLUDING CHARCOAL
EP3873987A4 (en) POLYGLYCOLIDE COPOLYMER COMPOSITION AND CORRESPONDING PREPARATION
JP1714197S (ja)
JP1708119S (ja)